Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country symbols : Ymab save search
Y-mAbs Announces Publication in Cancers Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment
Published: 2023-10-16 (Crawled : 22:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 1.13%
H: 6.53%
C: 0.75%
publication treatment
Y-mAbs Announces Presentation of Naxitamab data at AACR
Published: 2023-04-18 (Crawled : 16:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 3.77%
H: 0.0%
C: -7.26%
presentation
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
Published: 2023-04-05 (Crawled : 16:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -1.04%
H: 5.27%
C: 4.39%
trial
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
Published: 2023-03-30 (Crawled : 22:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -0.31%
H: 3.72%
C: 1.86%
financial results
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 0.43%
H: 4.29%
C: 3.43%
agreement
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-03 (Crawled : 16:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 1.23%
H: 3.44%
C: -2.63%
conference therapeutics
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
Published: 2022-12-21 (Crawled : 15:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 0.2%
H: 3.43%
C: -3.23%
partnership europe danyelza program
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: -0.86%
danyelza treatment approved china
Y-mAbs to Host Annual Research and Development Day in New York
Published: 2022-12-06 (Crawled : 18:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -2.95%
H: 5.14%
C: 0.7%
day research
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Update: Kaplan Fox Continues to Investigate Potential Securities Fraud
Published: 2022-12-02 (Crawled : 19:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -4.44%
H: 5.58%
C: -1.4%
potential
Y-mAbs Announces Pivotal Data for Omburtamab
Published: 2022-10-03 (Crawled : 15:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 1.6%
H: 0.48%
C: -9.35%
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab
Published: 2022-09-01 (Crawled : 21:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -1.55%
H: 1.45%
C: 1.14%
fda meeting
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
Published: 2022-08-02 (Crawled : 13:20) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -0.79%
H: 10.77%
C: 7.07%
results
Y-mAbs’ Announces Clearance of IND for GD2-SADA
Published: 2022-07-12 (Crawled : 20:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 0.88%
H: 7.46%
C: 2.62%
clearance
Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review
Published: 2022-05-31 (Crawled : 18:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -0.51%
H: 11.03%
C: 7.24%
omblastys treatment fda application license review
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
Published: 2022-04-01 (Crawled : 17:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 1.85%
H: 14.21%
C: 7.93%
fda application license submission
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
Published: 2022-02-11 (Crawled : 14:30) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 3.82%
H: 0.0%
C: 0.0%
fda
Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-05 (Crawled : 15:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -0.03%
H: 1.73%
C: -8.39%
health thc conference therapeutics j.p. morgan healthcare conference
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: 0.97%
H: 3.54%
C: -1.49%
disease treatment fda rare pediatric disease designation granted designation rare
Y-mAbs Announces Data to be Presented at SIOP 2021
Published: 2021-09-16 (Crawled : 14:00) - biospace.com/
YMAB | $14.91 3.76% 3.62% 300K
|
Health Technology
|
| O: -1.3%
H: 1.5%
C: 1.47%
presentation
Gainers vs Losers
| 47% | 53% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.